These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 10413303

  • 1. Effect of glutathione depletion on inhibition of cell cycle progression and induction of apoptosis by melphalan (L-phenylalanine mustard) in human colorectal cancer cells.
    Vahrmeijer AL, van Dierendonck JH, Schutrups J, van de Velde CJ, Mulder GJ.
    Biochem Pharmacol; 1999 Aug 15; 58(4):655-64. PubMed ID: 10413303
    [Abstract] [Full Text] [Related]

  • 2. Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine.
    Kramer RA, Greene K, Ahmad S, Vistica DT.
    Cancer Res; 1987 Mar 15; 47(6):1593-7. PubMed ID: 3815359
    [Abstract] [Full Text] [Related]

  • 3. Buthionine sulphoximine alone and in combination with melphalan (L-PAM) is highly cytotoxic for human neuroblastoma cell lines.
    Anderson CP, Tsai J, Chan W, Park CK, Tian L, Lui RM, Forman HJ, Reynolds CP.
    Eur J Cancer; 1997 Oct 15; 33(12):2016-9. PubMed ID: 9516845
    [Abstract] [Full Text] [Related]

  • 4. The glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan activity against preclinical models of multiple myeloma.
    Tagde A, Singh H, Kang MH, Reynolds CP.
    Blood Cancer J; 2014 Jul 18; 4(7):e229. PubMed ID: 25036800
    [Abstract] [Full Text] [Related]

  • 5. Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy.
    Anderson CP, Reynolds CP.
    Bone Marrow Transplant; 2002 Aug 18; 30(3):135-40. PubMed ID: 12189530
    [Abstract] [Full Text] [Related]

  • 6. Potentiation of the cytostatic effect of melphalan on colorectal cancer hepatic metastases by infusion of buthionine sulfoximine (BSO) in the rat: enhanced tumor glutathione depletion by infusion of BSO in the hepatic artery.
    Vahrmeijer AL, van Dierendonck JH, Schutrups J, van de Velde CJ, Mulder GJ.
    Cancer Chemother Pharmacol; 1999 Aug 18; 44(2):111-6. PubMed ID: 10412944
    [Abstract] [Full Text] [Related]

  • 7. Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line.
    Anderson CP, Seeger RC, Satake N, Monforte-Munoz HL, Keshelava N, Bailey HH, Reynolds CP.
    J Pediatr Hematol Oncol; 2001 Nov 18; 23(8):500-5. PubMed ID: 11878777
    [Abstract] [Full Text] [Related]

  • 8. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione.
    Bailey HH, Mulcahy RT, Tutsch KD, Arzoomanian RZ, Alberti D, Tombes MB, Wilding G, Pomplun M, Spriggs DR.
    J Clin Oncol; 1994 Jan 18; 12(1):194-205. PubMed ID: 8270977
    [Abstract] [Full Text] [Related]

  • 9. Effect of glutathione depletion on antitumor drug toxicity (apoptosis and necrosis) in U-937 human promonocytic cells. The role of intracellular oxidation.
    Troyano A, Fernández C, Sancho P, de Blas E, Aller P.
    J Biol Chem; 2001 Dec 14; 276(50):47107-15. PubMed ID: 11602574
    [Abstract] [Full Text] [Related]

  • 10. Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione.
    Ozols RF, Louie KG, Plowman J, Behrens BC, Fine RL, Dykes D, Hamilton TC.
    Biochem Pharmacol; 1987 Jan 01; 36(1):147-53. PubMed ID: 3801051
    [Abstract] [Full Text] [Related]

  • 11. Mechanisms involved in the potentiation of melphalan by the bioreductive compound THNLA-1 in vitro.
    Papadopoulou MV, Ji M, Khan SH, Bloomer WD.
    Oncol Res; 1999 Jan 01; 11(8):345-57. PubMed ID: 10803738
    [Abstract] [Full Text] [Related]

  • 12. Enhancement of melphalan activity by buthionine sulfoximine and electroporation in melanoma cells.
    Ongaro A, Pellati A, De Mattei M, De Terlizzi F, Rossi CR, Campana LG.
    Anticancer Drugs; 2015 Mar 01; 26(3):284-92. PubMed ID: 25514113
    [Abstract] [Full Text] [Related]

  • 13. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer.
    O'Dwyer PJ, Hamilton TC, LaCreta FP, Gallo JM, Kilpatrick D, Halbherr T, Brennan J, Bookman MA, Hoffman J, Young RC, Comis RL, Ozols RF.
    J Clin Oncol; 1996 Jan 01; 14(1):249-56. PubMed ID: 8558205
    [Abstract] [Full Text] [Related]

  • 14. Buthionine sulfoximine induction of gamma-L-glutamyl-L-cysteine synthetase gene expression, kinetics of glutathione depletion and resynthesis, and modulation of carmustine-induced DNA-DNA cross-linking and cytotoxicity in human glioma cells.
    Ali-Osman F, Antoun G, Wang H, Rajagopal S, Gagucas E.
    Mol Pharmacol; 1996 Jun 01; 49(6):1012-20. PubMed ID: 8649339
    [Abstract] [Full Text] [Related]

  • 15. Glutathione depletion by L-buthionine sulfoximine antagonizes taxol cytotoxicity.
    Liebmann JE, Hahn SM, Cook JA, Lipschultz C, Mitchell JB, Kaufman DC.
    Cancer Res; 1993 May 01; 53(9):2066-70. PubMed ID: 8097674
    [Abstract] [Full Text] [Related]

  • 16. Nitrogen mustard-DNA interaction in melphalan-resistant mammary carcinoma cells with elevated intracellular glutathione and glutathione-S-transferase activity.
    Alaoui-Jamali MA, Panasci L, Centurioni GM, Schecter R, Lehnert S, Batist G.
    Cancer Chemother Pharmacol; 1992 May 01; 30(5):341-7. PubMed ID: 1505071
    [Abstract] [Full Text] [Related]

  • 17. Reduced thiol content in L1210 cells treated with BSO increases DNA crosslinking by melphalan.
    Dorr RT.
    Biochem Biophys Res Commun; 1987 Apr 14; 144(1):47-52. PubMed ID: 3579919
    [Abstract] [Full Text] [Related]

  • 18. Synergism of buthionine sulfoximine and melphalan against neuroblastoma cell lines derived after disease progression.
    Anderson CP, Keshelava N, Satake N, Meek WH, Reynolds CP.
    Med Pediatr Oncol; 2000 Dec 14; 35(6):659-62. PubMed ID: 11107141
    [Abstract] [Full Text] [Related]

  • 19. Role of glutathione depletion and reactive oxygen species generation in apoptotic signaling in a human B lymphoma cell line.
    Armstrong JS, Steinauer KK, Hornung B, Irish JM, Lecane P, Birrell GW, Peehl DM, Knox SJ.
    Cell Death Differ; 2002 Mar 14; 9(3):252-63. PubMed ID: 11859408
    [Abstract] [Full Text] [Related]

  • 20. Cytotoxic effects of glutathione synthesis inhibition by L-buthionine-(SR)-sulfoximine on human and murine tumor cells.
    Dorr RT, Liddil JD, Soble MJ.
    Invest New Drugs; 1986 Mar 14; 4(4):305-13. PubMed ID: 3583642
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.